Biostar Technologies

Name

Biostar Technologies

Legal name

Beijing Biostar Pharmaceuticals Co., Ltd.

Website

https://biostar-pharm.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Beijing Biostar Pharmaceuticals (2563.HK) is a Chinese biopharmaceutical company that develops novel anti-tumor drugs via proprietary synthetic biology platforms, with its lead product Utidelone injection approved in China for advanced breast cancer and a 19-project pipeline targeting breast cancer brain metastases, gastric, pancreatic, lung, and ovarian cancers.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology drug development
• Anti-tumor biopharmaceuticals
• Synthetic biology drugs
• Microtubule stabilizer therapeutics
• Innovative cancer drug R&D

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Utidelone Injection Sales: Sales of Utidelone injection (brand name: 优替帝), a Class 1 innovative drug approved by NMPA in March 2021 for treatment of advanced and metastatic breast cancer. Listed in 2022 National Medical Insurance Drug Catalog.
2. Regional Licensing and Co-development: Out-licensing and co-development deals for Utidelone injection and capsule in international markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Biostar Technologies develops and commercializes innovative anti-tumor drugs built on proprietary synthetic biology platforms, with one NMPA-approved commercial product — Utidelone injection (优替帝) for advanced breast cancer — and 19 pipeline projects across NSCLC, ovarian, gastric, pancreatic, and other solid tumor indications. The company manufactures its drugs through microbial fermentation at its Chengdu facility, distributes them in China via Baheal Medical, and out-licenses regional rights to global pharmaceutical partners.

Product overview

Biostar Technologies is a computer hardware manufacturer offering a diverse portfolio of products including industrial motherboards and fanless IPC systems for AIoT and edge computing applications, consumer motherboards for gaming and productivity builds, graphics cards, and memory/storage solutions. The company has recently expanded into AI computing with NVIDIA Jetson Orin-based edge solutions and collaborative AI products developed with partners DEEPX and MemryX.

Differentiator

Problem solved

Functional benefit

Brands

• 优替帝 (Utide): Brand name for Utidelone injection product
• Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd.

Products and services

• Utidelone injection (优替帝) Utidelone injection is a novel microtubule stabilizer (epothilone analog) NMPA-approved for advanced/metastatic breast cancer, including patients who have failed taxane-based chemotherapy and those with brain metastases. It is administered to oncology patients in Chinese hospitals and distributed exclusively through Baheal Medical.
• Utidelone oral capsule Oral capsule formulation of Utidelone being developed as a non-infusion alternative to the injectable product for advanced breast cancer and other solid tumor indications, currently in Phase III clinical development.
• ADC (Antibody-Drug Conjugate) Platform Candidates ADC pipeline products leveraging the company's epothilone payload chemistry and synthetic biology platform to develop targeted antibody-drug conjugates for solid tumors.
• Utidelone new indication pipeline (NSCLC, ovarian, pancreatic, gastric cancers) Pipeline program extending the approved Utidelone microtubule stabilizer into additional oncology indications — NSCLC, ovarian cancer, pancreatic cancer, and gastric cancer — including orphan drug designations in pancreatic and gastric cancers.

Quantifiable outcome

• Phase III trial: significantly improved progression-free survival and overall survival vs standard regimens in advanced breast cancer
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Baheal Medical (百洋医药)coreChannel Partner/ Reseller/ Distributor · 8 May 2026Baheal Medical invested approximately 1 billion HKD through subscription of 25 million new shares, acquiring 7.49% stake. Holds exclusive marketing rights for Utidelone injection in mainland China. IPO cornerstone investor and strategic partner.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 15 December 2025Participating institution in UTD1 plus capecitabine pivotal US clinical trial for HER2-negative breast cancer brain metastases (NCT06764940)
• John Hopkins Sidney Kimmel Comprehensive Cancer CentercoreStrategic or Co-development Partner · 15 December 2025Participating institution in UTD1 plus capecitabine pivotal US clinical trial for HER2-negative breast cancer brain metastases
• City of Hope-Duarte Cancer CentercoreStrategic or Co-development Partner · 15 December 2025Participating institution in US pivotal clinical trial for breast cancer brain metastases
• Northwestern University Robert H. Lurie Comprehensive Cancer CentercoreStrategic or Co-development Partner · 15 December 2025Participating institution in US pivotal clinical trial for breast cancer brain metastases
• UT Southwestern Medical CentercoreStrategic or Co-development Partner · 15 December 2025US clinical trial site for BG02-2404 study (UTD2 gastric cancer international multi-regional Phase II/III trial)
• US Clinical Trial Network (20 cancer centers)minorStrategic or Co-development Partner · 15 December 2025Approximately 20 US oncology centers participating in pivotal clinical trials for breast cancer brain metastases indication
• Global Business Development PartnerscoreStrategic or Co-development PartnerActively seeking global partners for out-licensing or co-development of Utidelone injection and capsule. Contact via [email protected].

Scale indicators4 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Cstone Pharmaceuticals: HKEX-listed Chinese innovative oncology biotech with a similar profile of one or more commercialized/novel oncology assets and a heavy pipeline focus. Comparable as a peer-stage Chinese oncology drug developer using novel mechanisms and indication expansion strategies.
• Hutchmed (China MediTech): HKEX- and NASDAQ-listed Chinese oncology biotech commercializing novel targeted therapies through global development and out-licensing. Comparable to Biostar in pursuing a China-rooted novel-mechanism oncology franchise with international licensing as the growth lever.
• Akeso, Inc. Hong Kong-listed Chinese biotech focused on novel oncology antibodies and bispecifics. Comparable to Biostar as a similarly staged HKEX-listed Chinese innovator driving a differentiated oncology pipeline.
• RemeGen Co., Ltd. HKEX-listed Chinese biotech commercializing innovative biologics in oncology. Comparable as a peer in stage, listing venue, and focus on novel oncology biologics from a domestic innovation platform.
• Shanghai Junshi Biosciences: HKEX-listed Chinese biotech commercializing innovative oncology biologics including immuno-oncology therapies. Comparable as a peer-stage Chinese oncology innovator with similar global development ambitions.

Broad incumbents

• Innovent Biologics: Established HKEX-listed Chinese biotech with multiple commercial oncology assets including PD-1 inhibitors. Comparable as a broader incumbent in Chinese innovative oncology, though larger and more diversified than Biostar's single-asset focus.
• BeiGene: Global Chinese oncology company with commercialized BTK and PD-1 inhibitors. Comparable as a broader oncology incumbent, but operates at materially larger scale and global commercial footprint.
• Hansoh Pharmaceutical Group: Large HKEX-listed Chinese pharmaceutical company with multiple oncology and CNS drugs. Comparable as a broader incumbent in oncology innovative drugs, though operating at substantially greater commercial scale.
• Bristol-Myers Squibb: Global oncology incumbent with the established taxane franchise (paclitaxel, nab-paclitaxel, cabazitaxel) that competes directly with Utidelone's microtubule stabilization mechanism. Comparable as the dominant incumbent in the microtubule stabilizer category.
• Shanghai Fosun Pharmaceutical: Major Chinese pharmaceutical group with established oncology portfolio and licensing partnerships. Comparable as a broader incumbent actively pursuing innovative oncology assets and global licensing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biostar Technologies